Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
rhC1INH
DRUG
4 trials
Sponsors
Pharming Technologies B.V.
, University of Wisconsin, Madison
Conditions
Hereditary Angioedema
Kidney Failure
Phase 1
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
NCT03791476
University of Wisconsin, Madison
Kidney Failure
Start: 2019-06-21
End: 2022-01-31
Target: 20
Updated: 2020-12-14
Phase 2
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Completed
NCT01359969
Pharming Technologies B.V.
Hereditary Angioedema
Start: 2012-01-17
End: 2017-07-17
Updated: 2024-03-29
Phase 3
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks
Completed
NCT01188564
Pharming Technologies B.V.
Hereditary Angioedema
Start: 2011-01-31
End: 2013-03-31
Updated: 2015-08-07
Unknown Phase
Patient Registry to Evaluate the Real-world Safety of Ruconest®
Completed
NCT03697187
Pharming Technologies B.V.
Hereditary Angioedema
Start: 2018-06-30
End: 2021-07-31
Updated: 2024-04-05
Related Papers
Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema.
2026-05-20
Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks
Allergy Asthma and Clinical Immunology
2025-03-15
2 citations